223 related articles for article (PubMed ID: 31511184)
1. A Systematic Review of Decision-Analytic Models for Evaluating Cost-Effectiveness of Asthma Interventions.
Ehteshami-Afshar S; Zafari Z; Hamidi N; FitzGerald JM; Lynd L; Sadatsafavi M
Value Health; 2019 Sep; 22(9):1070-1082. PubMed ID: 31511184
[TBL] [Abstract][Full Text] [Related]
2. A Systematic Review of Health Economics Simulation Models of Chronic Obstructive Pulmonary Disease.
Zafari Z; Bryan S; Sin DD; Conte T; Khakban R; Sadatsafavi M
Value Health; 2017 Jan; 20(1):152-162. PubMed ID: 28212957
[TBL] [Abstract][Full Text] [Related]
3. Incorporating adherence in cost-effectiveness analyses of asthma: a systematic review.
Chongmelaxme B; Chaiyakunapruk N; Dilokthornsakul P
J Med Econ; 2019 Jun; 22(6):554-566. PubMed ID: 30663455
[No Abstract] [Full Text] [Related]
4. Cost Effectiveness of Pharmacological Treatments for Asthma: A Systematic Review.
Rodriguez-Martinez CE; Sossa-Briceño MP; Castro-Rodriguez JA
Pharmacoeconomics; 2018 Oct; 36(10):1165-1200. PubMed ID: 29869050
[TBL] [Abstract][Full Text] [Related]
5. Cost-Effectiveness of Biological Asthma Treatments: A Systematic Review and Recommendations for Future Economic Evaluations.
McQueen RB; Sheehan DN; Whittington MD; van Boven JFM; Campbell JD
Pharmacoeconomics; 2018 Aug; 36(8):957-971. PubMed ID: 29736895
[TBL] [Abstract][Full Text] [Related]
6. Systematic review of the economic evaluations of novel therapeutic agents in multiple myeloma: what is the reporting quality?
Aguiar PM; Lima TM; Storpirtis S
J Clin Pharm Ther; 2016 Apr; 41(2):189-97. PubMed ID: 27009796
[TBL] [Abstract][Full Text] [Related]
7. Systematic Review of Modelling Approaches for the Cost Effectiveness of Hepatitis C Treatment with Direct-Acting Antivirals.
Chhatwal J; He T; Lopez-Olivo MA
Pharmacoeconomics; 2016 Jun; 34(6):551-67. PubMed ID: 26748919
[TBL] [Abstract][Full Text] [Related]
8. A cost-effectiveness analysis of first-line controller therapies for persistent asthma.
Shih YC; Mauskopf J; Borker R
Pharmacoeconomics; 2007; 25(7):577-90. PubMed ID: 17610338
[TBL] [Abstract][Full Text] [Related]
9. Development of an economic model to assess the cost effectiveness of asthma management strategies.
Price MJ; Briggs AH
Pharmacoeconomics; 2002; 20(3):183-94. PubMed ID: 11929348
[TBL] [Abstract][Full Text] [Related]
10. Optimizing the position and use of omalizumab for severe persistent allergic asthma using cost-effectiveness analysis.
Faria R; McKenna C; Palmer S
Value Health; 2014 Dec; 17(8):772-82. PubMed ID: 25498772
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of asthma therapy: a comprehensive review.
Domínguez-Ortega J; Phillips-Anglés E; Barranco P; Quirce S
J Asthma; 2015; 52(6):529-37. PubMed ID: 25539023
[TBL] [Abstract][Full Text] [Related]
12. Consolidated Health Economic Evaluation Reporting Standards (CHEERS)--explanation and elaboration: a report of the ISPOR Health Economic Evaluation Publication Guidelines Good Reporting Practices Task Force.
Husereau D; Drummond M; Petrou S; Carswell C; Moher D; Greenberg D; Augustovski F; Briggs AH; Mauskopf J; Loder E;
Value Health; 2013; 16(2):231-50. PubMed ID: 23538175
[TBL] [Abstract][Full Text] [Related]
13. The role of decision analytic modeling in the health economic assessment of spinal intervention.
Edwards NC; Skelly AC; Ziewacz JE; Cahill K; McGirt MJ
Spine (Phila Pa 1976); 2014 Oct; 39(22 Suppl 1):S16-42. PubMed ID: 25299257
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of omalizumab add-on to standard-of-care therapy in patients with uncontrolled severe allergic asthma in a Brazilian healthcare setting.
Suzuki C; Lopes da Silva N; Kumar P; Pathak P; Ong SH
J Med Econ; 2017 Aug; 20(8):832-839. PubMed ID: 28532191
[TBL] [Abstract][Full Text] [Related]
15. Systematic review and economic analysis of the comparative effectiveness of different inhaled corticosteroids and their usage with long-acting beta2 agonists for the treatment of chronic asthma in children under the age of 12 years.
Main C; Shepherd J; Anderson R; Rogers G; Thompson-Coon J; Liu Z; Hartwell D; Loveman E; Green C; Pitt M; Stein K; Harris P; Frampton GK; Smith M; Takeda A; Price A; Welch K; Somerville M
Health Technol Assess; 2008 May; 12(20):1-174, iii-iv. PubMed ID: 18485272
[TBL] [Abstract][Full Text] [Related]
16. Generalisability in economic evaluation studies in healthcare: a review and case studies.
Sculpher MJ; Pang FS; Manca A; Drummond MF; Golder S; Urdahl H; Davies LM; Eastwood A
Health Technol Assess; 2004 Dec; 8(49):iii-iv, 1-192. PubMed ID: 15544708
[TBL] [Abstract][Full Text] [Related]
17. Systematic assessment of decision-analytic models for chronic myeloid leukemia.
Rochau U; Schwarzer R; Jahn B; Sroczynski G; Kluibenschaedl M; Wolf D; Radich J; Brixner D; Gastl G; Siebert U
Appl Health Econ Health Policy; 2014 Apr; 12(2):103-15. PubMed ID: 24385259
[TBL] [Abstract][Full Text] [Related]
18. Pharmacoeconomics Evaluations of Oral Anticancer Agents: Systematic Review of Characteristics, Methodological Trends, and Reporting Quality.
Al Kadour A; Marridi WA; Al-Badriyeh D
Value Health Reg Issues; 2018 Sep; 16():46-60. PubMed ID: 30144775
[TBL] [Abstract][Full Text] [Related]
19. Asthma Cost-Effectiveness Analyses: Are We Using the Recommended Outcomes in Estimating Value?
Kim CH; Dilokthornsakul P; Campbell JD; van Boven JFM
J Allergy Clin Immunol Pract; 2018; 6(2):619-632. PubMed ID: 28967548
[TBL] [Abstract][Full Text] [Related]
20. Modeling Approaches in Cost-Effectiveness Analysis of Disease-Modifying Therapies for Relapsing-Remitting Multiple Sclerosis: An Updated Systematic Review and Recommendations for Future Economic Evaluations.
Hernandez L; O'Donnell M; Postma M
Pharmacoeconomics; 2018 Oct; 36(10):1223-1252. PubMed ID: 29971666
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
